Clinical Trial: A Registry-study of ELZONRIS in Participants With BPDCN

U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07785154) titled 'A Registry-study of ELZONRIS in Participants With BPDCN' on Aug. 20.

Brief Summary: The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.

Study Start Date: June 26, 2024

Study Type: OBSERVATIONAL

Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Intervention: DRUG: Tagraxofusp

No study medication will be provided by the sponsor during this study.

Recruitment Status: RECRUITING

Sponsor: Stemline Therapeutics, Inc.

Published by HT Digital Content Services with permission fr...